Maintenance Olaparib Rechallenge for Platinum-Sensitive Relapsed Ovarian Cancer Previously Treated With a PARP Inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Ann. Oncol 2023 Oct 03;[EPub Ahead of Print], E Pujade-Lauraine, F Selle, G Scambia, B Asselain, F Marmé, K Lindemann, N Colombo, R Mądry, R Glasspool, I Vergote, J Korach, S Lheureux, C Dubot, A Oaknin, C Zamagni, F Heitz, L Gladieff, MJ Rubio-Pérez, P Scollo, C Blakeley, B Shaw, I Ray-Coquard, A RedondoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.